Seeking Alpha

German Merck signs collaboration deal for PARP inhibitor

  • Merck KGaA (MKGAF) inks a second collaboration deal with Beijing-based BeiGene.
  • The new deal is a licensing, development, and commercialization agreement for BeiGene-290, a preclinical PARP inhibitor.
  • The terms of the agreement call for German Merck to take on the development and commercialization responsibilities for '290 outside of China.
  • Milestone payments to BeiGene could reach $232M.
  • BeiGene also received an undisclosed upfront payment. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: